我们是否在治疗真正的中轴型脊柱关节炎女性患者?
该研究基于西班牙La Paz大学医院前瞻性队列中385例接受生物制剂治疗的中轴型脊柱关节炎(axSpA)患者的基线数据,比较2013年前后(即生物制剂获批用于非放射学axSpA前后)女性比例及疾病特征的变化。结果显示两时期女性比例无显著差异(38% vs 39%,p=0.8),但2013年后开始治疗的女性较之前有更高的全身炎症、活动度及功能受限。
要点
- 生物制剂获批用于nr-axSpA后,临床实践中启动治疗的女性比例未增加。
- 2013年后启动生物制剂的女性较之前具有更高的CRP、BASMI、BASDAI、ASDAS及BASFI。
- 2013年后启动生物制剂的nr-axSpA患者中,多数(60%)为男性。
核心结论
- 在本临床实践中,自生物制剂获批用于非放射学axSpA后,启动生物制剂治疗的女性频率并未增加。
- 2012年后接受生物制剂治疗的女性较获批前具有更多客观疾病活动度指标异常。
研究设计与样本
- 研究分析了西班牙马德里La Paz大学医院风湿科前瞻性进行中队列的基线数据集,纳入所有接受生物制剂治疗的axSpA患者。
- 根据生物制剂获批用于nr-axSpA的日期,将患者按首次生物制剂开始日期分为两个时期:时期1(2013年前)和时期2(2013年及以后)。
- 共385例患者启动生物制剂治疗,其中时期1有266例(69%),时期2有119例(31%)。
主要发现
- 两个时期之间性别分布无显著差异(女性分别为38%和39%;p=0.8)。
- 在时期2启动生物制剂的nr-axSpA患者中,大多数(60%)为男性。
- 时期2启动生物制剂的女性与时期1女性相比,中位(四分位距)CRP为10.2 mg/l(3.0-24.9)vs 3.2 mg/l(2.0-9.4),p=0.02;BASMI为2.7(1.8-3.5)vs 2.0(1.2-2.6),p=0.01。
- 时期2女性与时期2男性相比,BASDAI为6.5(5.4-8.0)vs 5.8(4.6-6.8),p=0.02;ASDAS均值(标准差)为3.6 ± 3.4 vs 3.2 ± 1.0,p=0.02;BASFI为5.7(3.8-6.7)vs 4.3(2.0-6.1),p=0.01。
临床怎么用
- 临床实践中应关注女性axSpA患者启动生物制剂治疗时的疾病活动度及功能状态,尤其2013年后女性患者可能具有更高的炎症和活动度指标。
- 对于nr-axSpA患者,启动生物制剂治疗时需注意性别差异,男性占多数,但女性患者可能病情更重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: During the last years, regulatory agencies raised some relevant concerns with regard to the possibility of administrating biological therapy (BT) to non-SpA patients. Especially, the possibility of treating women with fibromyalgia as non-radiographic axSpA (nr-axSpA) was mentioned. OBJECTIVES: To evaluate if the gender distribution and clinical pattern of patients with axSpA initiating biological therapy (BT) was modified in clinical practice after its approval for non radiographic-axSpA (nr-axSpA). METHODS: Baseline dataset from a prospective ongoing cohort including all patients with axSpA treated with BT at the Rheumatology Department of University Hospital La Paz, Madrid, Spain, was analysed. Patient's characteristics and disease activity parameters were collected. Based on the approval indication date of BT for nr-axSpA, patients were classified in two periods according to the starting date for the first BT: period 1 (before 2013) and period 2 (during or after 2013). Gender distribution and disease' characteristics were compared between both groups using Chi-square and Student-t tests. RESULTS: In total, 385 patients initiated BT: 266 (69%) in period 1 and 119 (31%) in period 2. No significant differences between both periods were observed regarding gender distribution (38% and 39% of women; p = 0.8). Out of those patients with nr-axSpA initiating BT in period 2, the majority (60%) were men. Women starting BT in period 2 had significantly higher systemic inflammation and mobility restriction compared with women in period 1 [median (interquartile range) CRP 10.2 mg/l (3.0-24.9) vs 3.2 mg/l (2.0-9.4); p = 0.02 and BASMI 2.7 (1.8-3.5) vs. 2.0 (1.2-2.6); p = 0.01, respectively]. In addition, they also presented significantly higher disease activity [BASDAI 6.5 (5.4-8.0) vs. 5.8 (4.6-6.8); p = 0.02; ASDAS, mean (SD) 3.6 ± 3.4 vs. 3.2 ± 1.0; p = 0.02, respectively] and more functional limitation [BASFI 5.7 (3.8-6.7) vs. 4.3 (2.0-6.1); p = 0.01, respectively] than men treated in period 2. CONCLUSIONS: In our clinical practice, the frequency of women who started BT did not increase since their approval for nr-axSpA. Women treated with BT after 2012 had more objective disease activity parameters than before their approval for nr-axSpA treatment.
引用
- Nieto RE, Plasencia Rodriguez C, Peiteado López D, et al. Are we treating women patients with real axial spondyloarthritis? Semin Arthritis Rheum. 2019. PMID: 31812352. doi:10.1016/j.semarthrit.2019.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。